



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428      **Phone:** (800) 745-7318

## Antiretroviral Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M      Member's place of residence  home  nursing facility

### Medication information

#### Antiretroviral requested

- |  |  |
|--|--|
| <input type="checkbox"/> Apretude (cabotegravir injection)   | <input type="checkbox"/> Rukobia (fostemsavir)   |
| <input type="checkbox"/> Cimduo (lamivudine/tenofovir disoproxil fumarate)                         | <input type="checkbox"/> Temixys (lamivudine/tenofovir disoproxil fumarate)              |
| <input type="checkbox"/> efavirenz/lamivudine/tenofovir disoproxil fumarate (600 mg/300 mg/300 mg) | <input type="checkbox"/> tenofovir disoproxil fumarate tablet > 1 unit/day               |
| <input type="checkbox"/> efavirenz/lamivudine/tenofovir disoproxil fumarate (400 mg/300 mg/300 mg) | <input type="checkbox"/> Tivicay (dolutegravir) > 1 unit/day                             |
| <input type="checkbox"/> maraviroc   | <input type="checkbox"/> Trogarzo (ibalizumab-uiyk)                                      |
| <input type="checkbox"/> nevirapine extended-release   | <input type="checkbox"/> Viread (tenofovir disoproxil fumarate) powder ≥ 13 years of age |

**Dose, frequency, and duration of medication requested** \_\_\_\_\_

#### Indication (Check all that apply.)

- HIV-1 Current viral load and date \_\_\_\_\_  
 pre-exposure prophylaxis (PreEP)  
 Chronic Hepatitis B       Other (specify) \_\_\_\_\_

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer care coordination services to this member. Please describe which additional behavioral health services would be beneficial.

### Section I. Please complete for requests for tenofovir disoproxil fumarate tablet > 1 unit/day, and Viread powder ≥ 13 years of age.

Please describe the medical necessity for the agent selected. Please address need for the requested quantity (tenofovir disoproxil fumarate tablet), or use in the requested age group (Viread powder), as appropriate.

---

**Section II. Please complete for Tivicay requests > 1 unit/day.**

1. Will the member be taking the requested medication concurrently with carbamazepine, efavirenz, fosamprenavir/ritonavir, Aptivus (tipranavir)/ritonavir, or rifampin?  
 Yes. Please document drug name with dose and frequency.  No  
Drug \_\_\_\_\_ Dose and Frequency \_\_\_\_\_
2. Does the member have integrase strand transfer inhibitor (INSTI)-associated resistance substitutions or clinically suspected INSTI-resistance?  
 Yes  No

---

**Section III. Please complete for nevirapine extended-release requests.**

Please attach medical records documenting an inadequate response or adverse reaction to nevirapine immediate-release formulation.

---

**Section IV. Please complete for Cimduo, efavirenz/lamivudine/tenofovir disoproxil fumarate, and Temixys requests.**

1. Please provide clinical rationale for use of the combination product instead of the individual agents.  
\_\_\_\_\_  
\_\_\_\_\_
2. For members < 18 years of age, please provide member's current weight. \_\_\_\_\_
3. For Cimduo and Temixys, will the member be taking the requested medication concurrently with at least one other antiretroviral?  
 Yes. Please document drug name with dose and frequency.  No  
Drug \_\_\_\_\_ Dose and Frequency \_\_\_\_\_

---

**Section V. Please complete for Rukobia requests.**

1. Is the member antiretroviral-experienced with documented historical or baseline resistance, intolerability, and/or contraindication to antiretroviral?  
 Yes. Please document drug name and outcome.\*  No  
Drug \_\_\_\_\_  Intolerability  Resistant  Other  
Briefly describe details of intolerability, resistance, or other.  
\_\_\_\_\_
2. Has the member failed current antiretroviral regimen due to resistance, intolerance, or safety considerations?  
 Yes. Please document drug name and outcome.\*  No  
Drug \_\_\_\_\_  Intolerability  Resistant  Other  
Briefly describe details of intolerability, resistance, or other.  
\_\_\_\_\_
3. Will the member be taking the requested medication concurrently with at least one other antiretroviral?  
 Yes. Please document drug name with dose and frequency.  No  
Drug \_\_\_\_\_ Dose and Frequency \_\_\_\_\_

---

**Section VI. Please complete for Trogarzo requests.**

1. Does the member have resistance to an agent from each of the three classes of antiretrovirals [nucleoside analog reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI)]?  
 Yes. Please document drug names and outcomes.\*  No  
NRTI \_\_\_\_\_  Resistant  Other  
NNRTI \_\_\_\_\_  Resistant  Other  
PI \_\_\_\_\_  Resistant  Other

Briefly describe details of resistance or other.

2. Will the member be taking the requested medication concurrently with at least one other antiretroviral?  
 Yes. Please document drug name with dose and frequency.  No  
Drug \_\_\_\_\_ Dose and Frequency \_\_\_\_\_

---

**Section VII. Please complete for Apretude requests.**

1. Please provide member's current weight. \_\_\_\_\_
2. Is the member HIV-negative?  Yes  No
3. Is the member considered at risk for acquiring HIV infection?  Yes  No
4. Please provide clinical rationale for use instead of emtricitabine/tenofovir disoproxil fumarate.  
\_\_\_\_\_  
\_\_\_\_\_
5. Please provide clinical rationale for use instead of Descovy.  
\_\_\_\_\_  
\_\_\_\_\_

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_

\* Required

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_